Mangoceuticals, Inc. (MGRX)
| Market Cap | 9.55M-81.3% |
| Revenue (ttm) | 315.23K |
| Net Income | -16.28M |
| EPS | -1.02 |
| Shares Out | 21.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,801 |
| Open | 0.43 |
| Previous Close | 0.44 |
| Day's Range | 0.43 - 0.45 |
| 52-Week Range | 0.16 - 2.75 |
| Beta | 1.98 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About MGRX
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
$MGRX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MGRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MGRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MGRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MGRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MGRX from public contracts
Source: USAspending.gov
MGRX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MGRX’s recent data — informational, not investment advice